OSAKA/TOKYO -- A cell therapy startup founded by Shimon Sakaguchi, a winner of the 2025 Nobel Prize in physiology or medicine, and others plans to launch its first clinical trial targeting autoimmune diseases in the U.S. as early as 2026.
Pharmaceuticals
Nobel winner Sakaguchi's cell therapy startup to launch US clinical trial
Testing will focus on role of regulatory T-cells in fighting autoimmune diseases
Shimon Sakaguchi, seen here in 2017, shared a 2025 Nobel Prize for his research on the immune system. (Photo by Hirofumi Yamamoto)
Read Next
Latest on Pharmaceuticals
